Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis

HPB

Volumn 12, Issue 1, 2010, Pages 37-42

  Chaudhury, Prosanto ^a   Hassanain, Mazen ^a   Bouganim, Nathaniel ^b   Salman, Ayat ^a   Kavan, Petr ^b   Metrakos, Peter ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Bevacizumab; Colon cancer liver metastasis; Liver resection; Peri operative chemotherapy

Indexed keywords

BEVACIZUMAB; IRINOTECAN; OXALIPLATIN;

ABDOMINAL ABSCESS; ADULT; AGED; ANASTOMOSIS DEHISCENCE; ANGIOPLASTY; ARTICLE; BILE LEAKAGE; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIARRHEA; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FATTY LIVER; FEMALE; HEART INFARCTION; HEPATITIS; HUMAN; LIVER FUNCTION; LIVER METASTASIS; LIVER RESECTION; MALE; MORBIDITY; PERIOPERATIVE PERIOD; PNEUMONIA; PREOPERATIVE PERIOD; STENT; SURGICAL MORTALITY; TREATMENT RESPONSE; URINARY TRACT INFECTION; WOUND INFECTION;

EID: 75449110555     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2009.00119.x     Document Type: Article

References (31)

1. American Cancer Society. (2008) Cancer Facts & Figures 2008. Atlanta: American Cancer Society.
2. Scheele J, Stangl R, Altendorf-Hofmann A. (1990) Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Brit J Surg 77:1241-1246.
3. Zelek L, Bugat R, Cherqui D, Ganem G, Valleur P, Guimbaud R et al. (2003) Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). [See comment.] Annal Oncol 14:1537-1542.
4. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. (2004) Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 240:438-447; discussion 447-450.
5. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD et al. (2002) Trends in longterm survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759-766.
6. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C et al. (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715-722; discussion 722-724.
7. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947.
8. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D et al. (1996) Resection of non-resectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509-520; discussion 520-522.
9. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D et al. (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict longterm survival. Ann Surg 240:644-657; discussion 657-658.
10. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P et al. (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup Trial 40983): a randomized controlled trial. Lancet 371:1007-1016.
11. Rubbia Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M et al. (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15:460-466.
12. Parikh AA, Gentner B, Wu T-T, Curley SA, Ellis LM, Vauthey J-N. (2003) Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 7:1082-1088.
13. Blazer DG III, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ et al. (2008) Pathologic response to preoperative chemotherapy: a new outcome endpoint after resection of hepatic colorectal metastases. J Clin Oncol 26:5344-5351.
14. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342.
15. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R et al. (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-2019.
16. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S et al. (2008) Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26:5254-5260.
17. D'Angelica M, Kornprat P, Gonen M, Chung KY, Jarnagin WR, DeMatteo RP et al. (2007) Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched casecontrol study. Ann Surg Oncol 14:759-765.
18. Reddy SK, Morse MA, Hurwitz HI, Bendell JC, Gan TJ, Hill SE et al. (2008) Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206:96-106.
19. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F et al. (2008) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26:1830-1835.
20. Dindo D, Demartines N, Clavien PA. (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205-213.
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. (2000) New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216.
22. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al. (2005) Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology 41:1313-1321.
23. Schindl MJ, Redhead DN, Fearon KC, Garden OJ, Wigmore SJ. (2005) The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection. Gut 54:289-296.
24. Schindl MJ, Millar AM, Redhead DN, Fearon KC, Ross JA, Dejong CH et al. (2006) The adaptive response of the reticuloendothelial system to major liver resection in humans. Ann Surg 243:507-514.
25. Saif MW, Elfiky A, Salem RR. (2007) Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14:1860-1869.
26. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. (2007) Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94:274-286.
27. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM et al. (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065-2072.
28. Sahajpal A, Vollmer CM Jr, Dixon E, Chan EK, Wei A, Cattral MS et al. (2007) Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect perioperative outcomes. J Surg Oncol 95:22-27.
29. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B et al. (2006) Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243:1-7.
30. Znajda TL, Hayashi S, Horton PJ, Martinie JB, Chaudhury P, Marcus VA et al. (2006) Postchemotherapy characteristics of hepatic colorectal metastases: remnants of uncertain malignant potential. J Gastrointest Surg 10:483-489.
31. Giantonio BJ, Levy DE, O'Dwyer PJ, Meropol NJ, Catalano PJ, Benson AB III (2006) A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 17:1399-1403.